Impact Analysis of Covid-19 The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters. Request Sample

Tylosin Market – Insights

Tylosin is an antibiotic that belongs to the class of macrolide antibiotics. It functions by binding to 50S ribosomal subunit and then interacts with 23S RNA thereby blocking aminoacyl-tRNA, which in turn inhibits protein synthesis. Tylosin is manufactured by fermentation of the bacterium— Streptomyces fradiae and is most effective against gram-positive bacteria compared to gram negative bacteria. The antibiotics is used to treat various infections in animals and respiratory infections in animals caused by Pasteurella multocida, Mannheimia haemolytica, and Haemophilus spp.

According to a report by Canadian Food Inspection Agency, 2014, 11 concentrations of tylosin used for therapeutic purposes, range from 44 mg kg-1 to 110 mg kg-1 feed. Moreover, tylosin is used in pigs to treat porcine proliferative enteropathy caused by Lawsonia intracellularis — a Gram-negative bacterium. Agriculture grade Tylosin consists of 80-90% tylosin A, with smaller amounts of tylosin B, tylosin C, and tylosin D. Around 29% of the active tylosin can be recovered in fecal samples in animals that receive tylosin, orally.

Tylosin is structurally related to erythromycin — another macrolide antibiotic, which is used in humans and animals. Macrolides may be used to treat infections in humans caused by Streptococcus pneumoniae, S. pyogenes, Staphylococcus aureus, and some other pathogens such as Legionella pneumophila, Chlamydophila pneumoniae, and Mycoplasma pneumonia.

Continuous demand for tylosin in livestock industry is expected to propel growth of the global tylosin market over the forecast period

Antimicrobial medications are generally used in the livestock industry for treatment of various infections in the livestock, prevention of disease, and to improve growth rate of the animals efficiency. Moreover, antimicrobial medications have been found to be effective in animals for improving growth rate and increasing weight more efficiently, which in turn results in increasing profits for the meat producers.

According to National Center for Biotechnology Information (NCBI), 2015, around 80% of antibiotics sold in the U.S. are for animal agriculture and almost 70% of these are medically important (i.e. from classes’ important to human medicine). Moreover, according to NCBI, the antimicrobial consumption in livestock is expected to increase by 67% by 2030, and nearly double in Brazil, Russia, India, China, and South Africa. These factors are expected to boost the global Tylosin market growth over the forecast period.

Rising income levels and disposable income in emerging economies such as Asia-Pacific has caused increase in demand for healthy protein sources for consumption as daily protein need of the body is not met through conventional food sources. According to NCBI, 2015, in Asia, the daily animal protein intake increased from 7 grams per capita per day to 25 grams per capita per day between 1960, and 2013. Countries such as Brazil, Russia, India, China, and South Africa (BRICS) have started implementing intensive livestock production systems to meet this demand (which necessitates use of antimicrobials). These factors are expected to support growth of the global Tylosin market over the forecast period.

The global Tylosin market size was valued at US$ 379.0 million in 2017, and is expected to witness a CAGR of 1.2% over the forecast period (2018 – 2026).

Figure 1. Global Tylosin Market Share (%), by Region, 2017

Source: Coherent Market Insights Analysis (2017)

Increasing demand for healthy livestock is expected to support growth of global Tylosin market over the forecast period

The demand for livestock animals for consumption is on the rise worldwide and is expected to maintain the positive growth in demand over the forecast period. Subsequently, the demand for infection-free and healthy livestock used primarily for consumption is increasing. However, the prevalence of various microbial infections is high in both humans and animals. For instance, according to the Centers for Disease Control and Prevention (CDC), 2017, zoonotic diseases are common in the U.S. and worldwide and over 6 out of every 10 known infectious diseases in humans are spread from animals. Hence, antibiotics are an important medication for livestock that aide in providing healthy food products for consumption in humans.

Moreover, antibiotics such as Tylosin are used in various animal species for prevention of mycoplasmosis. For instance, animals such as chickens, turkeys, pigs, and calves require oral Tylosin to be administered in required dosage to prevent mycoplasmosis and to grow healthy livestock. Furthermore, livestock is a major source of income in several of the emerging economies such as Brazil, which is major factor expected to contribute in growth of the market in the region over the forecast period.

However, increasing antimicrobial resistance in livestock is expected to restrain growth of the global Tylosin market over the forecast period. For instance, in 2013, University of California, San Francisco (UCSF) Academic Senate passed a resolution to restrict purchase of meat raised with nontherapeutic antibiotics.

Key players operating in the global Tylosin market include Zoetis, Tairui Pharmaceuticals, Lukang Pharmaceutical, Henan Hualun, Qilu Pharmaceutical (Inner Mongolia) Co., Ltd, Huvepharma, AdvaCare Pharma, and Elanco Animal Health.